Incara cell line could speed artificial liver:
This article was originally published in Clinica
Incara Pharmaceuticals is to be awarded a patent on an isolated hepatocyte precursor cell, which can differentiate into a hepatocyte. It plans to inject these cells, which have the potential to grow into functioning liver tissue, into patients as an alternative to whole organ transplant or for patients ruled out for that procedure. Such a cell line would also have potential for those companies presently researching the development of a bioartificial liver device.
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.